Carboplatin 450mg/45ml injection

Ferron Par Pharmaceuticals

Ingredients in every 45 ml

Carboplatin 450 mg

Each package contains

1 vial of 45 ml

Other details

Dosage form:Injection
Flavour: None

W.H.O. classification

ATC Level 1: L - Antineoplastic and immunomodulating agents
ATC Level 2: L01 - Antineoplastic Agents
ATC Level 3: L01X - Other Antineoplastic Agents in ATC



NOT SAFEThis item is not safe for use during pregnancy.


NOT SAFEThis item is not safe for use during lactation.


CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.


CAUTIONThis item may not be safe for use while operating heavy machinery. Use with caution.

Available in


Dosage information

The recommended dose of carboplatin in previously untreated adults patients with normal kidney is 400 mg/m² as a single intravenous infusion over 15-60 minutes.
Therapy should not be repeated until four weeks after the previous carboplatin course and/or the neutrophil count is at least 2,000 cells/mm³ and the platelet count is at least 100,000 cells/mm³.
It is recommended that according to clinical circumstances, the initial dosage may require reduction by 20-25% in patients with risk factors such as previous myelosuppressive therapy and poor performance status.
Determination of hematological nadir by weekly blood counts during initial courses is recommended for future dosage adjustment and scheduling of carboplatin.

Combination therapy
The optimal use of carboplatin in combination with other myelosuppressive agents requires dosage adjustments according to the regimen and schedule to be adopted.


– Advanced ovarian carcinoma
– Small cell and non-small cell carcinoma of the lung
– Squamous cell carcinoma of the head and neck
– Advanced transitional cell carcinoma of the bladder
– Significant responses have been observed when carboplatin employed in the treatment of carcinoma of the cervix

Carboplatin is frequently used in combination with other chemotherapeutic agent in various indications, such as with paclitaxel in first line therapy of ovarian carcinoma and non-small cell lung carcinoma.


The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for informational purposes only. This tool may not cover all possible drug interactions or all warnings or alerts. Please check with a physician if you have health questions or concerns about interactions or go to the appropriate government authority for a comprehensive list of medical warnings. Although we attempt to provide accurate and up-to-date information, no guarantee is made to that effect.

All of the content present on this website, including written text, photographs, videos, graphics, and other resources we might include (these will fall under the collective term of “website”), is meant to educate and should not be perceived as a substitution for professional medical advice, diagnosis or treatment. You should not resort to the website information to arrive at a diagnosis or treatment solution for your health problems or various medical conditions. It does not replace medical care, provided by a medical specialist. In the situation, you have specific symptoms and you might suspect that you are suffering from a medical problem, it is for the best to consult your physician.